Drug Profile
PF 3654764
Alternative Names: PF-03654764Latest Information Update: 29 Sep 2010
Price :
$50
*
At a glance
- Originator Pfizer
- Class Neuropsychotherapeutics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Alzheimer's disease
Most Recent Events
- 27 Sep 2010 Discontinued - Phase-I for Alzheimer's disease in Singapore (PO)
- 27 Sep 2010 Discontinued - Phase-II for Allergic rhinitis in Canada (PO)
- 31 May 2010 Pfizer completes a phase II trial in Allergic rhinitis in Canada